Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $2.71 Million Position in BioMarin Pharmaceutical Inc. $BMRN

Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 8.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 49,273 shares of the biotechnology company’s stock after purchasing an additional 3,716 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in BioMarin Pharmaceutical were worth $2,709,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BMRN. Rise Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 1st quarter valued at $30,000. V Square Quantitative Management LLC acquired a new stake in BioMarin Pharmaceutical during the second quarter valued at $25,000. Brooklyn Investment Group boosted its position in BioMarin Pharmaceutical by 2,250.0% during the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 540 shares during the last quarter. Hantz Financial Services Inc. grew its stake in BioMarin Pharmaceutical by 480.2% in the second quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 874 shares in the last quarter. Finally, Banque Transatlantique SA acquired a new position in BioMarin Pharmaceutical in the 1st quarter worth about $71,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BMRN. Guggenheim raised their price target on BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Morgan Stanley cut their price objective on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 28th. Zacks Research downgraded shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Wall Street Zen lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 8th. Sixteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $52.56 on Thursday. The company has a current ratio of 4.83, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The firm has a fifty day simple moving average of $53.71 and a 200-day simple moving average of $56.33. The stock has a market capitalization of $10.10 billion, a price-to-earnings ratio of 19.76, a PEG ratio of 0.68 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a 1-year low of $50.76 and a 1-year high of $73.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Monday, October 27th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.20). The firm had revenue of $776.13 million during the quarter, compared to the consensus estimate of $782.42 million. BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The business’s revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.91 EPS. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. On average, sell-side analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.